Guangzhou Zhongwei Biotechnology

Guangzhou Zhongwei Biotechnology is a clinical-stage biopharmaceutical company based in China that focuses on the development of mRNA-based vaccines and therapeutics. As a subsidiary of Sirnaomics, the company leverages the proprietary Z-mRNA platform and advanced lipid nanoparticle (LNP) delivery systems to create highly effective nucleic acid drugs. Its pipeline includes candidates for infectious diseases, such as COVID-19 and rabies, as well as therapeutic vaccines for oncology. The company's lead program, ZW001, has advanced into Phase 2 clinical trials for COVID-19 prevention. Zhongwei Biotech maintains integrated capabilities for mRNA sequence design, delivery vehicle optimization, and large-scale GMP manufacturing.